A Multicenter, Single-Arm, Open-Label Treatment Use Protocol for Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma
Several clinical studies indicate that pomalidomide has activity in relapsed and refractory
multiple myeloma with response rates ranging between 30% and 60% at pomalidomide doses at 2
mg/day and/or 4 mg/day.
Expanded Access
N/A
Lars Sternas, MD, PhD
Study Director
Celgene Corporation
United States: Food and Drug Administration
CC-4047-MM-009
NCT01632826
Name | Location |
---|---|
Celgene Study Site | Greenbrae, California 94904 |
Celgene Study Site | Denver, Colorado 80218 |
Celgene Study Site | West Palm Beach, Florida 33401 |
Celgene Study Site | Marietta, Georgia 30060 |
Celgene Study Site | Peoria, Illinois 61615 |
Celgene Study Site | Indianapolis, Indiana 46202 |
Celgene Study Site | Iowa City, Iowa 52242 |
Celgene Study Site | Baltimore, Maryland 21215 |
Celgene Study Site | Hyannis, Massachusetts 02601 |
Celgene Study Site | St. Louis, Missouri 63110 |
Celgene Study Site | Omaha, Nebraska 68198 |
Celgene Study Site | Hackensack, New Jersey 07601 |
Celgene Study Site | New York, New York 10029 |
Celgene Study Site | Philadelphia, Pennsylvania 19107 |
Celgene Study Site | Greenville, South Carolina 29615 |
Celgene Study Site | Sioux Falls, South Dakota 57105 |
Celgene Study Site | Dallas, Texas 75390 |
Celgene Study Site | Salt Lake City, Utah 84106 |
Celgene Study Site | Morgantown, West Virginia 26506 |
Celgene Study Site | Milwaukee, Wisconsin 53226 |